MYLAN 9 4 (Carbidopa and levodopa extended release 50 mg / 200 mg)

Pill imprint MYLAN 9 4 has been identified as Carbidopa and levodopa extended release 50 mg / 200 mg.

Carbidopa/levodopa is used in the treatment of parkinson's disease; restless legs syndrome; neuroleptic malignant syndrome; gtp-ch deficiency and belongs to the drug class dopaminergic antiparkinsonism agents. Risk cannot be ruled out during pregnancy. Carbidopa/levodopa 50 mg / 200 mg is not subject to the Controlled Substances Act.

See also related documents.

Imprint Search

Images for MYLAN 9 4

Carbidopa and levodopa extended release 50 mg / 200 mg MYLAN 9 4 Front
Carbidopa and levodopa extended release 50 mg / 200 mg MYLAN 9 4 Back
Carbidopa and levodopa extended release 50 mg / 200 mg MYLAN 9 4
Carbidopa and levodopa extended release
Imprint:
MYLAN
9 4
Strength:
50 mg / 200 mg
Color:
Purple
Size:
13.00 mm
Shape:
Elliptical / Oval
Availability:
Prescription only
Drug Class:
Dopaminergic antiparkinsonism agents
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
N - Not a controlled drug
Manufacturer:
Mylan Pharmaceuticals Inc.
National Drug Code (NDC):
00378-0094
Inactive Ingredients:
FD&C Blue No. 2
FD&C Red No. 40
hydroxypropyl cellulose
hypromelloses
magnesium stearate
Other Manufacturers / Repackagers:
NDC CodeManufacturer / Repackager
51079-0923 UDL Laboratories Inc
68258-9026 Dispensing Solutions Inc. (repackager)
67544-0672 Prepak Systems Inc (repackager)

Note: Inactive ingredients may vary.

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2014 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide
(web5)